RecruitingNot ApplicableNCT06887556

Mpox Comprehensive Assessment for Responsive Immunisation in Emergency Outbreaks


Sponsor

University of Birmingham

Enrollment

650 participants

Start Date

Feb 5, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The MPXV CARE study principally aims to use clinical and epidemiology data to target specific individuals willing and able to provide appropriate and proportionate biological samples to develop novel immune diagnostics that support models of disease burden and future vaccine utilisation.


Eligibility

Min Age: 5 YearsMax Age: 80 Years

Inclusion Criteria9

  • Healthy males and females aged between ages 5-80 years, who are able and willing to provide informed consent and will comply with the study requirements.
  • Group 1 (suspected exposure cohort) only
  • Live within or adjacent to an epidemiologically identified region of Mpox transmission
  • Close contacts of those with microbiologically confirmed Mpox
  • Group 2 (post-exposure/vaccinated cohort) only
  • Previous clinically or microbiologically confirmed Mpox or confirmed previous vaccination with a smallpox/MVA vaccine
  • Fully recovered from Mpox infection
  • Group 3 (control cohort) only:
  • Asymptomatic with no known exposure to Mpox

Exclusion Criteria14

  • Unwilling or unable to provide informed consent to take part
  • Unwilling or unable to comply with study procedures
  • History of any suspected or confirmed disorder of the immune system that, in the opinion of the investigators, might impair the results of the study
  • Have a bleeding disorder deemed significant by a member of the study team
  • Pregnant or breast-feeding females
  • Group 1 (suspected exposure cohort) only
  • Known history of Mpox infection
  • Current symptoms consistent with Mpox
  • Known exposure to Mpox in the last month
  • Group 2 (post-exposure/vaccinated cohort) only
  • Participants with any ongoing symptoms of Mpox, indicating incomplete recovery.
  • Group 3 (control cohort only)
  • Symptoms of Mpox
  • Known exposure to Mpox in the last month

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTELISA

Mpox-specific antibody ELISA

DIAGNOSTIC_TESTLateral flow assay

Dried blood spot lateral flow assay for Mpox antibody


Locations(1)

Rwanda Biomedical Center

Kigali, Rwanda

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06887556


Related Trials